MARKET

LQDA

LQDA

Liquidia Technologies
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.72
+0.30
+4.67%
After Hours: 6.72 0 0.00% 16:00 01/21 EST
OPEN
6.51
PREV CLOSE
6.42
HIGH
7.10
LOW
6.35
VOLUME
263.24K
TURNOVER
--
52 WEEK HIGH
20.05
52 WEEK LOW
2.650
MARKET CAP
101.57M
P/E (TTM)
-2.6761
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of LQDA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

LQDA News

  • Will Liquidia Continue to Surge Higher?
  • Zacks.6d ago
  • Liquidia nets $22.4 million as it moves forward with lead drug
  • American City Business Journals.12/26/2019 19:55
  • Mid-Afternoon Market Update: Nasdaq Hits 9,000; Spring Bank Pharmaceuticals Shares Slide
  • Benzinga.12/26/2019 19:12
  • HEXO, SPPI, NLNK and ACST among midday movers
  • Seeking Alpha - Article.12/26/2019 17:38

More

Industry

Pharmaceuticals
-0.30%
Pharmaceuticals & Medical Research
-0.40%

Hot Stocks

Name
Price
%Change

About LQDA

Liquidia Technologies, Inc. is a clinical biopharmaceutical company, which is focused on the developing and commercialization of human therapeutics using its PRINT technology. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The Company is engaged in developing product candidates from its pipeline, LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. LIQ861 is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies. LIQ865, has completed a Phase Ib clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic and to treat local post-operative pain.
More

Webull offers Liquidia Technologies Inc (LQDA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.